They Removed the Tumor and the Weight Got Worse: Acquired Hypothalamic Obesity

Episode Overview

• Dr. Jordan Feigenbaum and Dr. Austin Baraki (both affiliated with Barbell Medicine, with no external sponsors or financial conflicts of interest disclosed) examine a medical case report of a 21-year-old patient who experienced rapid, uncontrollable weight gain and insatiable hunger even after the successful removal of a benign brain tumor and targeted hormone replacement therapy.
• The narrative progresses from the patient's surgical history—removing an adamantinomatous craniopharyngioma—to his post-operative complications, his eventual diagnosis of acquired hypothalamic obesity, and the clinical mechanics of pharmacological intervention.
• The speakers use this extreme clinical case to explain the neurobiology of the hypothalamus, breaking down how the POMC/MC4R "brake" and AgRP/NPY "accelerator" pathways govern appetite and energy expenditure.
• Ultimately, the episode connects rare structural and single-gene (monogenic) disorders to common polygenic obesity, helping listeners understand why appetite and body weight are primarily dictated by involuntary neurological circuits rather than conscious willpower.

Key Concepts

• Tumor Pathology and Post-Operative Hypothalamic Damage: The 21-year-old patient (who took 7 months to initially present to doctors) was diagnosed with an adamantinomatous craniopharyngioma—"adamant" meaning hard or unbreakable, resembling tooth-forming enamel tissue growing into a mass at the base of the brain rather than a reproductive germ cell tumor. Because the benign mass pressed on his optic nerves and threatened his pituitary gland, neurosurgery removed it via a transsphenoidal approach through the sphenoid bone to reach the sella ("saddle spot"), operating millimeters from the pituitary stalk. Immediately post-op, his vision improved, but he developed diabetes insipidus (putting out "liters of dilute urine") and acquired panhypopituitarism, requiring lifelong replacement therapy: hydrocortisone twice a day, testosterone every week, thyroid hormone every day, and desmopressin. Despite his replacement hormones being dialed in to target and repeat imaging showing no tumor recurrence, the tumor and surgery irreversibly damaged the appetite and satiety circuits in his hypothalamus. Over the 3 months following surgery, his appetite skyrocketed, he never felt full, and he gained another 33 pounds (reaching 60 or so pounds gained in total), leading to an official diagnosis of acquired hypothalamic obesity.
• The Hypothalamic Appetite Circuit (Brake vs. Accelerator): Body weight is primarily managed at the level of the hypothalamus, where genes set the lower and upper guardrails and the environment moves an individual around inside them. Within the hypothalamus sits the arcuate nucleus, a cluster of cells positioned where the blood-brain barrier is "leaky," allowing it to sample blood signals like ghrelin, leptin, insulin, PYY, and GLP-1. It houses two opposing neuron populations:
• The Brake (POMC/CART): When pro-opiomelanocortin (POMC) neurons fire, they chop POMC into smaller pieces, releasing alpha-MSH. This binds to the MC4R receptor in a neighboring region of the hypothalamus to reduce food-seeking behavior and increase energy expenditure.
• The Accelerator (AgRP/NPY): Neurons making agouti-related peptide (AgRP—named after a strain of fat yellow mice that led to its discovery) and neuropeptide Y (NPY, which Dr. Baraki remembers via the mnemonic "I Need Pizza Yesterday") promote appetite and food-seeking. AgRP travels to the same MC4R receptor and jams the lock so alpha-MSH cannot bind, while also directly silencing neighboring POMC neurons. In animal studies, switching on AgRP neurons makes a recently fed mouse eat immediately, while switching them off causes a starving mouse to walk past food.
• Leptin as a One-Way Low-Fuel Alarm: Fat tissue releases leptin in proportion to body fat mass, but the brain treats it strictly as a "low-fuel alarm" defending the floor, not the ceiling. When leptin falls, AgRP neurons fire harder, POMC neurons go quiet, hunger climbs, and the body throttles back energy expenditure and reproductive function (which can cause hypogonadism). Conversely, high leptin from carrying high body fat does not produce fullness, and flooding the system of people who carry high body fat with extra leptin does nothing, proving it is not an effective satiating hormone in common obesity.
• Monogenic vs. Polygenic Obesity and the Illusion of Willpower: Breaking any single link in the hypothalamic chain causes relentless hunger and childhood-onset monogenic obesity. Loss-of-function mutations in the MC4R receptor are the most common single-gene cause of obesity known, accounting for about 1 in 20 severe childhood obesity cases. Similarly, congenital leptin deficiency causes toddlers to experience ravenous hunger every waking minute (which is reversible by treating them with metreleptin to switch hunger off), and POMC deficiency causes severe obesity, red hair, and adrenal failure (lack of adrenal cortisol) because the POMC protein is chopped into pieces that perform multiple jobs. In contrast, "common obesity" is a polygenic "perfect storm" of subtle variations across many genes interacting with the modern environment. Citing Dr. Stephan Guyenet's book The Hungry Brain and decades of underlying research, Dr. Baraki notes that the vast majority of genetic variations implicated in common obesity regulate appetite in the brain rather than peripheral fat cell function (contradicting claims made by the low-carb community). While Dr. Feigenbaum hedges that "it is possible that there are... pleiotropic effects of some of these genetic differences" affecting both weight regulation and environmental responses ("willpower"), both speakers emphasize that decisions at the dinner table are heavily driven by upstream neurobiology.

Quotes

• At 9:00 - "Now, this tumor, this craniopharyngioma sat right on those nerve cells, right? Right on that circuit. And the surgery to remove it, you know, damaged that area too. So now the brake was gone. Um, effectively this individual was persistently hungry, persistently seeking food, and yeah, un- unable to willpower himself out of this. So hunger was just on the whole time. Fullness never registered." - Dr. Feigenbaum explaining why the patient gained 33 pounds in the 3 months following successful tumor removal, illustrating how physical damage to the hypothalamus eliminates the neurological ability to feel full.
• At 16:35 - "If you switch on these agouti-related peptide neurons in a mouse that just finished a meal, it starts eating again almost immediately. If you switch them off in a starving mouse, it'll walk past the food. Uh, in humans, loss-of-function mutations in the MC4R, that receptor, uh, is the most common single-gene cause of obesity we know of." - Dr. Feigenbaum demonstrating the mechanical power of the AgRP "accelerator" and MC4R receptor in dictating food-seeking behavior across species.
• At 17:54 - "Leptin going up, though, from an individual with high body fat does not produce the mirror image. So somebody carrying around a lot of body fat has high leptin all day and they're not walking around full. Um, there was a thought that, well, this just means they're resistant to the leptin signal. As it turns out, that doesn't appear to be the case. You can give these people, you can flood their system with leptin and nothing happens still." - Dr. Feigenbaum debunking the common misconception that leptin acts as a two-way satiety hormone in common obesity.
• At 24:44 - "All of this is suggesting that the conscious-level choices that happen at the dinner table, at the, you know, in the kitchen, at the, you know, when you're out to eat or whatever, are not really as conscious as you would you would otherwise expect." - Dr. Feigenbaum synthesizing the episode's core message that upstream neurobiology heavily dictates behaviors people typically attribute to conscious willpower.

Takeaways

• Abandon "eat less, move more" advice in favor of targeted pharmacotherapy for biologically driven appetite: Telling patients to simply "eat less and move more" is generally ineffective for most people and will "definitively not work" when a secondary underlying driver causes insatiable appetite. Instead, clinicians should utilize targeted medical treatments such as GLP-1 receptor agonists like tirzepatide (which Dr. Baraki notes is their favorite at the moment) or setmelanotide, an MC4 receptor agonist with trial data showing specificity for managing hypothalamic obesity (Dr. Baraki reserves comment on other niche treatments with which he has less experience). In the case report, setmelanotide was not approved at the time, so the patient was placed on a sub-maximal dosage of tirzepatide and lost 9 kilograms (19 or 20 pounds) of the ~60 pounds gained over a 4-month follow-up period.
• Prioritize strict fluid and sodium monitoring when managing panhypopituitarism: When caring for post-operative pituitary patients, clinicians and patients must treat water regulation (diabetes insipidus managed with desmopressin) as the most difficult and critical aspect of the regimen. Taking too much or too little desmopressin, or drinking too much or too little fluid, leads to rapid and significant complications in water balance and blood sodium levels.
• Balance aggressive pharmacological intervention against patient treatment burden: While Dr. Feigenbaum questions whether losing only 20 of 60 pounds gained represents "suboptimal management" (hedging that the case report ended at 4 months on a sub-maximal dose of tirzepatide), Dr. Baraki notes it is "hard to say without being there" and highlights an important clinical lesson: clinicians must weigh the timing of new prescriptions against patient overwhelm. Delaying anti-obesity medication can be a deliberate, empathetic choice when a 21-year-old patient is already adjusting to invasive brain surgery and four new lifelong daily/weekly hormone medications, especially if clinicians hope weight gain might resolve spontaneously post-resection.